|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||144.52|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Osiris Therapeutics Inc. has hired a new CEO — its fourth since February 2016. Linda Palczuk, 55, will start in the position July 10, replacing Interim CEO David A. Dresner. Columbia-based Osiris, which develops drugs and medical treatments using stem cells, was delisted from the NASDAQ composite earlier this year after repeatedly failing to file financial statements with the U.S. Securities and Exchange Commission.
Categories: Yahoo Finance Osiris Therapeutics, Inc. relative valuation is UNDERVALUED and it has a fundamental analysis score of 86. Our analysis is based on comparing Osiris Therapeutics, Inc. with the following peers – Vericel Corporation, Integra LifeSciences Holdings Corporation, Geron Corporation, Johnson & Johnson, Xtant Medical Holdings, Inc., CONMED Corporation, Nektar Therapeutics and Pluristem Therapeutics Inc. (VCEL-US, IART-US, ... Read more (Read more...)
Osiris Therapeutics Inc. stock has received a delisting notice from the Nasdaq Stock Exchange and will be suspended from trading when the market opens Tuesday. The news sent Osiris shares down more than 10 percent Monday morning, trading at $4.66 per share. Osiris did not file its delinquent financial reports with the U.S. Securities Exchange Commission, the company reported Friday.